Central Nervous System Disease (CNS)

Categories: Immune diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Central Nervous System Disease

MalaCards integrated aliases for Central Nervous System Disease:

Name: Central Nervous System Disease 12 15 17
Central Nervous System Diseases 43
Cns Disorder 71
Cns 47


External Ids:

Disease Ontology 12 DOID:331
MeSH 43 D002493
NCIt 49 C2934
SNOMED-CT 67 23853001
ICD10 32 G96 G96.8 G96.9
UMLS 71 C0007682

Summaries for Central Nervous System Disease

Disease Ontology : 12 A nervous system disease that affects either the spinal cord (myelopathy) or brain (encephalopathy) of the central nervous system.

MalaCards based summary : Central Nervous System Disease, also known as central nervous system diseases, is related to meningoencephalitis and neuromyelitis optica, and has symptoms including headache, hemiplegia and hyperexplexia. An important gene associated with Central Nervous System Disease is HAR1A (Highly Accelerated Region 1A), and among its related pathways/superpathways are Neuroscience and IL-17 Family Signaling Pathways. The drugs Oseltamivir and Dexmedetomidine have been mentioned in the context of this disorder. Affiliated tissues include brain, spinal cord and t cells, and related phenotypes are cardiovascular system and cellular

Wikipedia : 74 Central nervous system diseases, also known as central nervous system disorders, are a group of... more...

Related Diseases for Central Nervous System Disease

Diseases in the Nervous System Disease family:

Autoimmune Disease of Central Nervous System Congenital Nervous System Abnormality
Central Nervous System Disease Infectious Disease of the Nervous System

Diseases related to Central Nervous System Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1792)
# Related Disease Score Top Affiliating Genes
1 meningoencephalitis 33.6 MBP CCR6 BDNF APP
2 neuromyelitis optica 33.5 MOG MBP GFAP
3 nervous system disease 33.1 TBK1 SERPINA3 PROM1 NOS2 MOG MMP9
4 encephalitis 32.1 NOS2 MOG IL1B GFAP
5 amyotrophic lateral sclerosis 1 32.0 TBK1 SERPINA3 NOS2 GFAP CCR6 BDNF
6 demyelinating disease 31.9 SERPINA3 MOG MMP9 MBP IL1B IFNG
7 autoimmune disease 31.7 MOG MMP9 MBP IL1B IFNG CXCR3
8 acquired immunodeficiency syndrome 31.7 NOS2 MBP IL1B IFNG CCR6
9 allergic encephalomyelitis 31.7 MOG MBP
10 traumatic brain injury 31.7 MMP9 MBP GFAP BDNF
11 viral encephalitis 31.7 MOG MBP IL1B CCR6
12 alzheimer disease 31.7 SOX2-OT SERPINA3 NOS2 IL1B HAR1A GRM2
13 brain injury 31.6 MBP GFAP BDNF
14 acute disseminated encephalomyelitis 31.6 MOG MBP IL1B CCR6
15 hydrocephalus 31.6 SERPINA3 MBP IFNG GFAP BDNF APP
16 neuritis 31.6 MOG MMP9 MBP IL1B IFNG GFAP
17 parkinson disease, late-onset 31.6 SERPINA3 MBP H19 GRM5 BDNF APP
18 subacute sclerosing panencephalitis 31.6 MOG MBP IFNG
19 myelitis 31.5 MOG MMP9 MBP CCR6
20 proteasome-associated autoinflammatory syndrome 1 31.5 NOS2 MMP9 IL1B IFNG
21 optic neuritis 31.5 MOG MBP IL1B GFAP CXCR3 BDNF
22 schizophrenia 31.5 SERPINA3 MOG MBP IL1B IFNG HAR1A
23 optic nerve disease 31.5 SERPINA3 MOG MBP GFAP CCR6 BDNF
24 spinal cord injury 31.5 NOS2 MMP9 GFAP BDNF
25 bacterial meningitis 31.4 MMP9 IL1B IFNG
26 relapsing-remitting multiple sclerosis 31.4 MOG MMP9 MBP IL1B IFNG CCR6
27 peripheral nervous system disease 31.4 SERPINA3 MOG MBP IL1B IFNG GFAP
28 dementia 31.4 TBK1 SERPINA3 GFAP BDNF APP
29 narcolepsy 31.3 MOG GFAP CCR1 BDNF
30 mycobacterium tuberculosis 1 31.3 SERPINA3 IFNG CXCR3 CCR6
31 trypanosomiasis 31.3 NOS2 IL1B IFNG CXCR3
32 status epilepticus 31.3 GRM5 GRM2 GFAP BDNF
33 toxic shock syndrome 31.2 NOS2 IL1B IFNG
34 toxoplasmosis 31.2 NOS2 IL1B IFNG
35 periventricular leukomalacia 31.2 NOS2 MBP APP
36 multiple sclerosis 31.2 NOS2 MOG MMP9 MBP IL1B IFNG
37 brain edema 31.1 NOS2 MMP9 IL1B IFNG GFAP
38 tropical spastic paraparesis 31.1 MMP9 IFNG CXCR3
39 secondary progressive multiple sclerosis 31.1 MMP9 MBP IFNG CXCR3 BDNF
40 gliosarcoma 31.1 SERPINA3 PROM1 MMP9 IFNG GFAP
41 eye disease 31.1 SERPINA3 MMP9 IL1B IFNG GFAP CCR6
42 sarcoidosis 1 31.1 SERPINA3 IL1B IFNG CXCR3 CCR6
43 vascular dementia 31.1 SERPINA3 MMP9 MBP IL1B APP
44 normal pressure hydrocephalus 31.1 SERPINA3 GFAP BDNF APP
45 spinal cord disease 31.1 MOG MBP GFAP CCR6
46 neuroblastoma 31.1 PROM1 MMP9 IFNG H19 GFAP BDNF
47 substance abuse 31.1 SERPINA3 MOG CCR6 BDNF
48 bacterial infectious disease 31.1 SERPINA3 IL1B IFNG CCR6
49 prion disease 31.1 SERPINA3 IL1B GFAP APP
50 psychotic disorder 31.1 SERPINA3 GRM5 GRM2 BDNF

Graphical network of the top 20 diseases related to Central Nervous System Disease:

Diseases related to Central Nervous System Disease

Symptoms & Phenotypes for Central Nervous System Disease

UMLS symptoms related to Central Nervous System Disease:

headache, hemiplegia, hyperexplexia

MGI Mouse Phenotypes related to Central Nervous System Disease:

# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.11 APP CCR1 CCR6 CXCR3 GFAP IFNG
2 cellular MP:0005384 10.1 APP BDNF CCR1 CXCR3 GFAP GRM2
3 hematopoietic system MP:0005397 10 APP CCR1 CCR6 CXCR3 IFNG IL1B
4 homeostasis/metabolism MP:0005376 9.97 APP BDNF CCR1 CCR6 CXCR3 GFAP
5 immune system MP:0005387 9.73 APP CCR1 CCR6 CXCR3 GFAP IFNG
6 nervous system MP:0003631 9.44 APP BDNF CCR6 GFAP GRM2 GRM5

Drugs & Therapeutics for Central Nervous System Disease

Drugs for Central Nervous System Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 284)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Oseltamivir Approved Phase 4 196618-13-0, 204255-11-8 65028
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 68602 5311068
Vigabatrin Approved Phase 4 60643-86-9, 68506-86-5 5665
Zidovudine Approved Phase 4 30516-87-1 35370
Lamivudine Approved, Investigational Phase 4 134678-17-4 60825
Efavirenz Approved, Investigational Phase 4 154598-52-4 64139
Nevirapine Approved Phase 4 129618-40-2 4463
Tenofovir Experimental, Investigational Phase 4 147127-20-6 464205
9 Antineoplastic Agents, Hormonal Phase 4
10 Analgesics Phase 4
11 Adrenergic Agonists Phase 4
12 Hypnotics and Sedatives Phase 4
13 Adrenergic alpha-2 Receptor Agonists Phase 4
14 Analgesics, Non-Narcotic Phase 4
15 Whey Protein Phase 4
16 Soy Bean Phase 4
17 Anti-HIV Agents Phase 4
18 GABA Agents Phase 4
19 Cytochrome P-450 Enzyme Inhibitors Phase 4
20 Anti-Retroviral Agents Phase 4
21 Reverse Transcriptase Inhibitors Phase 4
22 Cytochrome P-450 CYP3A Inducers Phase 4
23 Lamivudine, zidovudine drug combination Phase 4
24 Cytochrome P-450 CYP2C9 Inhibitors Phase 4
25 Anticoagulants Phase 4
Dopamine Approved Phase 3 51-61-6, 62-31-7 681
Donepezil Approved Phase 3 120014-06-4 3152
Pregabalin Approved, Investigational Phase 3 148553-50-8 5486971
Ganciclovir Approved, Investigational Phase 3 82410-32-0 3454
Aripiprazole Approved, Investigational Phase 3 129722-12-9 60795
Acyclovir Approved Phase 3 59277-89-3 2022
Cladribine Approved, Investigational Phase 3 4291-63-8 20279
Mitoxantrone Approved, Investigational Phase 3 65271-80-9 4212
Glyburide Approved Phase 3 10238-21-8 3488
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
Vincristine Approved, Investigational Phase 3 2068-78-2, 57-22-7 5978
Pegaspargase Approved, Investigational Phase 3 130167-69-0
Cytarabine Approved, Experimental, Investigational Phase 3 147-94-4, 65-46-3 6253
Daunorubicin Approved Phase 3 20830-81-3 30323
Etoposide Approved Phase 3 33419-42-0 36462
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
Mercaptopurine Approved Phase 3 50-44-2 667490
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865
Mechlorethamine Approved, Investigational Phase 3 51-75-2 4033
Ifosfamide Approved Phase 3 3778-73-2 3690
Vindesine Approved, Investigational Phase 3 53643-48-4, 59917-39-4 40839
Isotretinoin Approved Phase 3 4759-48-2 5538 5282379
Tetrabenazine Approved, Investigational Phase 3 58-46-8 6018

Interventional clinical trials:

(show top 50) (show all 237)
# Name Status NCT ID Phase Drugs
1 Banlangen Granules Anti-seasonal Influenza Study: a Randomized, Double Blind, Positive and Placebo Controlled,Clinical Study. Unknown status NCT02232945 Phase 4 placebo of oseltamivir phosphate;oseltamivir phosphate;Banlangen (Radix Isatidis) granules;placebo of Banlangen(Radix Isatidis) granules
2 The Effect of 6-Methyl-Prednisolone on Organ Dysfunction and Mortality of Patients With Unresolving Multiple Organ Dysfunction Syndrome Unknown status NCT00127985 Phase 4 6-methyl-prednisolone
3 Use of Dexmedetomidine for Prophylactic Analgesia and Sedation in Patients After Intracranial Surgery (Prophylactic Analgesia and Sedation Trial, PASTrial) Completed NCT01445639 Phase 4 Dexmedetomidine;Normal saline
4 Effect of Undenatured Cysteine-Rich Whey Protein Isolate (HMS 90®) in Patients With Parkinson's Disease: Changes in Biomarkers of Oxidative Stress, Profiles of Plasma Amino Acids and Their Derivatives and Brain Function Completed NCT01662414 Phase 4
5 A Prospective, Open-label Study of the Structure and Function of the Retina in Adult Patients With Refractory Complex Partial Seizures Treated With Vigabatrin (Sabril®) Completed NCT01278173 Phase 4 Sabril
6 Clinical Trial of CNS Penetrating ART to Prevent NeuroAIDS in China Completed NCT01340950 Phase 4 zidovudine-lamivudine-nevirapine;tenofovir-lamivudine-efavirenz
7 Detection of Silent Atrial Fibrillation aFter Ischemic StrOke (SAFFO) Guided by Implantable Loop Recorder. Multicentre Italian Trial Based on Stroke Unit Network With Paired Cardio-Arrhythmology Units (Italian Neurocardiology Unit Network) Recruiting NCT02684825 Phase 4
8 Intelligent Activity-based Client-centred Training Unknown status NCT02982811 Phase 3
9 A Multicenter, Open-label, Phase 3 Study to Determine the Safety and Efficacy of Gadobutrol 1.0 Molar (Gadavist) in Patients Referred for Contrast-enhanced MRI of the Central Nervous System (CNS). Completed NCT00623467 Phase 3 Gadobutrol (Gadavist, Gadovist, BAY86-4875)
10 A Randomized, Double-Blind, Placebo-Controlled Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia Completed NCT02195700 Phase 2, Phase 3 SD-809;Placebo
11 An Open-Label Long-Term Study Of Pregabalin For The Treatment Of Central Neuropathic Pain (Post Spinal Cord Injury Pain, Post Stroke Pain, And Multiple Sclerosis Pain) Completed NCT01202227 Phase 3 pregabalin
12 A Single-blind, Multicenter, Randomized, Phase III Study of the Efficacy and Safety of Gadavist (1.0 M) in Comparison With Magnevist (0.5 M) as Contrast Agent for Enhanced Magnetic Resonance Imaging (MRI) of Central Nervous System (CNS) Lesions in Chinese Patients Completed NCT00395460 Phase 3 Gadobutrol (Gadavist, Gadovist, BAY86-4875);Magnevist
13 A Multicenter, Open-Label, Long-Term Extension Of Phase III Studies (BN29552/BN29553) Of Crenezumab In Patients With Alzheimer's Disease Completed NCT03491150 Phase 3 Crenezumab (RO5490245)
14 A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia Completed NCT02291861 Phase 3 SD-809;Placebo
15 A 24-weeks, Multi-center, Randomized, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Donepezil Hydrochloride in Chinese Subjects With Severe Alzheimer's Disease Completed NCT01404169 Phase 3 E2020;Placebo
16 Phase III Randomized, Controlled Study of Ganciclovir for Symptomatic Congenital Cytomegalovirus Infection Completed NCT00004278 Phase 3 ganciclovir
17 Randomized, Multicenter, Double-blind, Double-dummy, Parallel-Group Study With an Open-label Extension Phase to Compare the Efficacy and Safety of Donepezil Hydrochloride 23 mg Treatment With Continuation of Donepezil Hydrochloride 10 mg Treatment in Japanese Subjects With Severe Alzheimer's Disease Completed NCT01539031 Phase 3 E2020;E2020
18 A Phase 3b, Open-Label, Randomized, Multicenter Study to Assess the Safety and Immunogenicity of GlaxoSmithKline Biologicals Meningococcal Group B Vaccine When Administered Concomitantly With GlaxoSmithKline Biologicals MenACWY Conjugate Vaccine to Healthy Infants Completed NCT02106390 Phase 3
19 An Open-Label, Multicenter Study Evaluating the Safety and Tolerability of Once-daily Oral Aripiprazole in Children and Adolescents With Tourette's Disorder Completed NCT01727713 Phase 3 Aripiprazole
20 A Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety and Efficacy of Fixed-Dose Once-daily Oral Aripiprazole in Children and Adolescents With Tourette's Disorder Completed NCT01727700 Phase 3 Aripiprazole;Placebo
21 A Multicenter, Randomized, Double-blind, Crossover, Phase 3 Study to Determine the Safety and Efficacy of Gadobutrol 1.0 Molar (Gadavist) in Patients Referred for Contrast-enhanced MRI of the Central Nervous System (CNS) Completed NCT00709852 Phase 3 Gadobutrol (Gadavist, Gadovist, BAY86-4875);Gadoteridol (ProHance)
22 Safety and Efficacy Evaluation of DOTAREM® in Magnetic Resonance Imaging (MRI) in Patients With Central Nervous System (CNS) Lesions. Completed NCT01211873 Phase 3 Dotarem (gadoterate meglumine);Magnevist (gadopentetate dimeglumine)
23 A Phase 3b, Open Label, Controlled, Multi-Center, Extension Study to Assess the Persistence of Bactericidal Activity at 4 to 7.5 Years After Two Dose Primary Series of GlaxoSmithKline Biologicals Meningococcal B Recombinant Vaccine and the Response to a Third Dose in Adolescents and Young Adult Subjects Who Previously Participated in Parent Studies V72_41 (NCT01423084) and V72P10 (NCT00661713), Compared to Naïve Healthy Controls Completed NCT02446743 Phase 3
24 A Placebo-Controlled Phase III Evaluation of Suppressive Therapy With Oral Acyclovir Suspension Following Neonatal Herpes Simplex Virus Infections Limited to the Skin, Eye, and Mouth Completed NCT00031447 Phase 3 Acyclovir;Placebo
25 A Collaborative Trial for the Treatment of Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplasia Completed NCT00136084 Phase 3 Cladribine, Cyclophosphamide, Cytarabine, Daunorubicin, Dexamethasone;Etoposide, Cytarabine, Gemtuzumab, L-asparaginase, Mercaptopurine, methotrexate, Mitoxantrone, Prednisone, Vincristine
26 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 (Glibenclamide) for Severe Cerebral Edema Following Large Hemispheric Infarction Recruiting NCT02864953 Phase 3 BIIB093;Placebo
27 Open-label, Single-arm, Multi-center Study of Intracerebral Administration of Adeno-associated Viral (AAV) Serotype rh.10 Carrying Human N-sulfoglucosamine Sulfohydrolase (SGSH) cDNA for Treatment of Mucopolysaccharidosis Type IIIA Recruiting NCT03612869 Phase 2, Phase 3 LYS-SAF302
28 DIRECT-SAFE: A Randomized Controlled Trial of DIRECT Endovascular Clot Retrieval Versus Standard Bridging Thrombolysis With Endovascular Clot Retrieval Within 4.5 Hours of Stroke Onset Recruiting NCT03494920 Phase 3
29 Modified BFM (Berlin-Frankfurt-Munster)Backbone Therapy for Chinese Children or Adolescents With Newly Diagnosed Lymphoblastic Lymphoma Recruiting NCT02845882 Phase 3 Prednisone,Vincristine, Pegylated-asparaginase, Cytarabine, Cyclophosphamide, Daunorubicin, 6-mercaptopurine;6-mercaptopurine,Methotrexate;Dexamethasone,Vincristine, Pegylated-asparaginase, Cytarabine, Cyclophosphamide, Doxorubicin, 6-mercaptopurine;Dexamethasone,Vincristine, Pegylated-asparaginase, Cytarabine, Cyclophosphamide, Methotrexate;Dexamethasone, Vindesine, Methotrexate, Ifosfamide, Daunorubicin, Pegylated-asparaginase;Dexamethasone, Cytarabine, Etoposide, Pegylated-asparaginase;Methotrexate, 6-mercaptopurine
30 European Low and Intermediate Risk Neuroblastoma Protocol Recruiting NCT01728155 Phase 3 chemotherapy
31 An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia Active, not recruiting NCT02198794 Phase 3 SD-809;Placebo
32 A Phase III Multi-centre Randomised, Double Blind, Placebo Controlled Trial to Assess the Role of Intravenous Immunoglobulin in the Management of Children With Encephalitis Active, not recruiting NCT02308982 Phase 3 Immunoglobulins, Intravenous (Privigen);Placebo
33 A Phase 3b Multicenter, Single-Arm, Open-Label Safety Study of LY2951742 (Galcanezumab) in Patients With Episodic or Chronic Cluster Headache Enrolling by invitation NCT02797951 Phase 3 Galcanezumab
34 A Phase III Multi-Center Open Label Study to Evaluate Safety and Efficacy of MultiHance at the Dose of 0.10 mmol/kg in Magnetic Resonance Imaging of the Central Nervous System in Pediatric Patients Terminated NCT00323310 Phase 3 gadobenate dimeglumine
35 A Randomized, Double-Blind, Placebo-Controlled and Delayed-Start Study of LY3314814 in Mild Alzheimer's Disease Dementia Terminated NCT02783573 Phase 3 Lanabecestat;Placebo
36 An Open-Label Extension To The B1451006 Protocol To Evaluate The Safety And Efficacy Of Dimebon (Latrepirdine, PF-01913539) In Subjects With Moderate-To-Severe Alzheimer's Disease Terminated NCT01066546 Phase 3 Dimebon tablet for oral administration
37 A Randomized, Double-Blind, Delayed-Start Study of LY3314814 (AZD3293) in Early Alzheimer's Disease Dementia (Extension of Study AZES, The AMARANTH Study) Terminated NCT02972658 Phase 3 Lanabecestat
38 A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study) Terminated NCT02245737 Phase 2, Phase 3 Lanabecestat;Placebo
39 Phase 2/3 Study of Intravenous Thrombolysis and Hypothermia for Acute Treatment of Ischemic Stroke Terminated NCT01123161 Phase 2, Phase 3 Group1: IV t-PA and normothermia
40 Autologous Bone Marrow Stromal Cell and Endothelial Progenitor Cell Transplantation in Patients With Ischemic Stroke: a Randomized Controlled Trial Unknown status NCT01468064 Phase 1, Phase 2
41 Phase I/II Study of Human Anti-Cytomegalovirus (CMV) Monoclonal Antibody MSL-109 in Newborns With Symptomatic Congenital CMV Infection Without Central Nervous System Disease Completed NCT00004642 Phase 1, Phase 2 SDZ MSL-109
42 A 52-week,Multi-center,Randomized,Double-blind,Placebo-controlled,Parallel Group Study in Patients With Mild Alzheimer's Disease to Investigate the Safety and Tolerability of Repeated Subcutaneous Injections of CAD106 Completed NCT00733863 Phase 2
43 A 52-week,Multi-center,Randomized,Double-blind,Placebo-controlled,Parallel Group Study in Patients With Mild Alzheimer's Disease to Investigate the Safety and Tolerability of Repeated Subcutaneous Injections of CAD106 Completed NCT00795418 Phase 2
44 An Open-label Extension to a 52-week, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study in Patients With Alzheimer's Disease to Investigate the Safety and Tolerability of Repeated Subcutaneous Injections of CAD106. Completed NCT01023685 Phase 2
45 A 90-week, Multi-center, Randomized, Double-blind, Placebo-controlled Study in Patients With Mild Alzheimer's Disease (AD) to Investigate the Safety, Tolerability and Abeta-specific Antibody Response Following Repeated i.m. Injections of Adjuvanted CAD106 Completed NCT01097096 Phase 2
46 An Open-label Extension to a 52-week, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study in Patients With Alzheimer's Disease to Investigate the Safety and Tolerability of Repeated Subcutaneous Injections of CAD106 Completed NCT00956410 Phase 2
47 A Multicenter, Open-label, Follow-up Study to Evaluate the Long-term Safety and Tolerability of BGG492 TID as Adjunctive Therapy in Patients With Partial Onset Seizures Completing Double-blind, Placebo-controlled Study CBGG492A2207 or CBGG492A2211 Completed NCT01338805 Phase 2 BGG492
48 A Randomized, Double-blind, Placebo-Controlled, Parallel, 24-Week, Phase 2 Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Subjects With Mild to Moderate Probable Alzheimer's Disease Completed NCT01073228 Phase 2 EVP-6124;Placebo
49 A Randomized Double-Blind Placebo-Controlled 12-Week Phase 2 Study of Two Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist(EVP-6124)or Placebo in Schizophrenia Subjects on Chronic Stable Atypical Anti-Psychotic Therapy Completed NCT00968851 Phase 2 EVP-6124;Placebo;EVP-6124
50 Pharmacokinetics and Safety of 50 mg/kg IV Levetiracetam (Keppra) in Full Term and Preterm Neonates Completed NCT01239212 Phase 1, Phase 2 levetiracetam

Search NIH Clinical Center for Central Nervous System Disease

Cochrane evidence based reviews: central nervous system diseases

Genetic Tests for Central Nervous System Disease

Anatomical Context for Central Nervous System Disease

MalaCards organs/tissues related to Central Nervous System Disease:

Brain, Spinal Cord, T Cells, Bone, B Cells, Testes, Myeloid

Publications for Central Nervous System Disease

Articles related to Central Nervous System Disease:

(show top 50) (show all 1838)
# Title Authors PMID Year
Reduced creatine kinase B activity in multiple sclerosis normal appearing white matter. 54 61
20520825 2010
Different proteolipid protein mutants exhibit unique metabolic defects. 54 61
19663806 2009
Partial characterization of the proteome of the mouse striatum. 54 61
17922512 2007
Sequence variation in the CC-chemokine ligand 2 promoter of pigtailed macaques is not associated with the incidence or severity of neuropathology in a simian immunodeficiency virus model of human immunodeficiency virus central nervous system disease. 54 61
17162657 2006
Prediction of neuropathology in mucopolysaccharidosis I patients. 54 61
15639191 2005
Cerebrospinal fluid and plasma concentrations of proinflammatory mediators in human immunodeficiency virus-infected children. 54 61
14872175 2004
Functional expression of chemokine receptor CCR5 on CD4(+) T cells during virus-induced central nervous system disease. 54 61
12477824 2003
Increased CCR5 affinity and reduced CCR5/CD4 dependence of a neurovirulent primary human immunodeficiency virus type 1 isolate. 54 61
12021361 2002
Increased macrophage chemoattractant protein-1 in cerebrospinal fluid precedes and predicts simian immunodeficiency virus encephalitis. 54 61
11574916 2001
Human umbilical cord blood cells ameliorate Alzheimer's disease in transgenic mice. 54 61
11563821 2001
Age-related CNS disorder and early death in transgenic FVB/N mice overexpressing Alzheimer amyloid precursor proteins. 54 61
7576662 1995
Fingolimod (FTY720) improves postoperative cognitive dysfunction in mice subjected to D-galactose-induced aging. 61
31960817 2020
Exercise in multiple sclerosis and its models: Focus on the central nervous system outcomes. 61
31486115 2020
Is the Arginase Pathway a Novel Therapeutic Avenue for Diabetic Retinopathy? 61
32033258 2020
Cheminformatics and virtual screening studies of COMT inhibitors as potential Parkinson's disease therapeutics. 61
31744341 2020
A Central Nervous System Disease of Unknown Cause That Occurred in the Minamata Region: Results of an Epidemiological Study. 61
31685726 2020
Autophagy activation is required for homocysteine-induced apoptosis in bovine aorta endothelial cells. 61
32021943 2020
Anti-CD20 Monoclonal Antibodies for Relapsing and Progressive Multiple Sclerosis. 61
31994023 2020
Emerging Pharmacological Treatments for Cerebral Edema: Evidence from Clinical Studies. 61
31914899 2020
Microvascular pericytes in brain-associated vascular disease. 61
31743876 2020
Potent, Selective, Water Soluble, Brain-Permeable EP2 Receptor Antagonist for Use in Central Nervous System Disease Models. 61
31904232 2020
miR-29a Promotes the Neurite Outgrowth of Rat Neural Stem Cells by Targeting Extracellular Matrix to Repair Brain Injury. 61
31885334 2019
Vaccine Oka Varicella Meningitis in Two Adolescents. 61
31776194 2019
Meta-transcriptomic identification of hepatitis B virus in cerebrospinal fluid in patients with central nervous system disease. 61
31451314 2019
Neonatal Herpes Simplex Virus-1 Recurrence with Central Nervous System Disease in Twins after Completion of a Six-Month Course of Suppressive Therapy: Case Report. 61
31887772 2019
[Research progress on the effects of plateau hypoxia on blood-brain barrier structure and drug permeability]. 61
31955542 2019
Inflammatory monocytes and neutrophils regulate Streptococcus suis-induced systemic inflammation and disease but are not critical for the development of central nervous system disease in a mouse model of infection. 61
31818962 2019
GINS complex subunit 2 (GINS2) plays a protective role in alcohol-induced brain injury. 61
30513217 2019
Expert insights: The potential role of the gut microbiome-bile acid-brain axis in the development and progression of Alzheimer's disease and hepatic encephalopathy. 61
31808182 2019
Neuron specific enolase as a marker of seizure related neuronal injury. 61
31404559 2019
Case report of neurotoxicity with blinatumomab and concurrent intrathecal chemotherapy in second relapse of acute lymphoblastic leukemia with central nervous system disease. 61
30537919 2019
Clinical significance of occult central nervous system disease in adult acute lymphoblastic leukemia. A multicenter report from the campus all network. 61
31879328 2019
Utility of Surface and Blood Polymerase Chain Reaction Assays in Identifying Infants With Neonatal Herpes Simplex Virus Infection. 61
31626049 2019
Clinical characteristics of human herpesvirus-6 myelitis after allogeneic hematopoietic stem cell transplantation and its favorable outcome by early intervention. 61
31754252 2019
The Spatial and Temporal Characters of Demyelination and Remyelination in the Cuprizone Animal Model. 61
31251832 2019
Lack of Efficacy of High-Titered Immunoglobulin in Patients with West Nile Virus Central Nervous System Disease. 61
31625835 2019
Predictors of damage accrual in systemic lupus erythematosus: a longitudinal observational study with focus on neuropsychological factors and anti-neuronal antibodies. 61
31367942 2019
Development of an immunochromatographic device to detect antibodies for rapid diagnosis of human angiostrongyliasis. 61
31690362 2019
The assessment of lenticulostriate arteries originating from middle cerebral artery using ultra high-field magnetic resonance time-of-flight angiography. 61
31331750 2019
Impact of Travel Distance on Radiation Treatment Modality for Central Nervous System Disease. 61
31831978 2019
[β Amyloid Hypothesis in Alzheimer's Disease:Pathogenesis,Prevention,and Management]. 61
31699204 2019
A case of immune reconstitution syndrome complicating progressive multifocal leukoencephalopathy after kidney transplant: Clinical, pathological, and radiographic features. 61
31419376 2019
Identification of Novel Adenosine Deaminase 2 Gene Variants and Varied Clinical Phenotype in Pediatric Vasculitis. 61
31008556 2019
Central nervous system disease in childhood acute lymphoblastic leukemia. 61
26990196 2019
Cerebrospinal pharmacokinetic and pharmacodynamic analysis of efficacy of meropenem in paediatric patients with bacterial meningitis. 61
31279154 2019
Phase II study of irinotecan and temozolomide in breast cancer patients with progressing central nervous system disease. 61
31172405 2019
Does CSF pleocytosis have a predictive value for disease course in MS? 61
31355320 2019
Neuroprotective effects of anthocyanins and its major component cyanidin-3-O-glucoside (C3G) in the central nervous system: An outlined review. 61
31238064 2019
A Confocal Reflection Super-Resolution Technique to Image Golgi-Cox Stained Neurons. 61
31237354 2019
Viral Sequences Detection by High-Throughput Sequencing in Cerebrospinal Fluid of Individuals with and without Central Nervous System Disease. 61
31431002 2019

Variations for Central Nervous System Disease

Expression for Central Nervous System Disease

Search GEO for disease gene expression data for Central Nervous System Disease.

Pathways for Central Nervous System Disease

GO Terms for Central Nervous System Disease

Cellular components related to Central Nervous System Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 astrocyte projection GO:0097449 8.62 GFAP APP

Biological processes related to Central Nervous System Disease according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 inflammatory response GO:0006954 9.8 TBK1 SERPINA3 IL1B CXCR3 CCR1
2 positive regulation of protein phosphorylation GO:0001934 9.73 MMP9 IL1B IFNG APP
3 cell chemotaxis GO:0060326 9.72 CXCR3 CCR6 CCR1
4 calcium-mediated signaling GO:0019722 9.71 CXCR3 CCR6 CCR1
5 chemokine-mediated signaling pathway GO:0070098 9.7 CXCR3 CCR6 CCR1
6 regulation of insulin secretion GO:0050796 9.67 NOS2 IL1B IFNG
7 negative regulation of gene expression GO:0010629 9.65 TBK1 NOS2 IFNG CCR1 APP
8 immune response GO:0006955 9.63 MBP IL1B IFNG CXCR3 CCR6 CCR1
9 modulation of age-related behavioral decline GO:0090647 9.51 GRM5 APP
10 positive regulation of receptor binding GO:1900122 9.48 MMP9 BDNF
11 positive regulation of interleukin-1 beta biosynthetic process GO:0050725 9.46 IFNG APP
12 positive regulation of killing of cells of other organism GO:0051712 9.37 NOS2 IFNG
13 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.32 IL1B IFNG
14 astrocyte activation GO:0048143 9.13 IL1B IFNG APP
15 positive regulation of chemokine biosynthetic process GO:0045080 8.8 IL1B IFNG APP

Molecular functions related to Central Nervous System Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 chemokine binding GO:0019956 9.43 CXCR3 CCR6 CCR1
2 C-C chemokine binding GO:0019957 9.33 CXCR3 CCR6 CCR1
3 C-C chemokine receptor activity GO:0016493 9.13 CXCR3 CCR6 CCR1
4 chemokine receptor activity GO:0004950 8.8 CXCR3 CCR6 CCR1

Sources for Central Nervous System Disease

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
31 HPO
32 ICD10
33 ICD10 via Orphanet
37 LifeMap
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
54 Novoseek
57 OMIM via Orphanet
61 PubMed
70 Tocris
72 UMLS via Orphanet
Loading form....